Evidence that Aβ42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype

Neurobiology of Disease

Volumn 6, Issue 4, 1999, Pages 280-287

  De Jonghe, Chris ^a   Cras, Patrick ^b,d   Vanderstichele, Hugo ^e   Cruts, Marc ^a   Vanderhoeven, Inge ^a   Smouts, Iris ^a   Vanmechelen, Eugeen ^e   Martin, Jean Jaques ^c,d   Hendriks, Lydia ^a   Van Broeckhoven, Christine ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e INNOGENETICS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; COMPLEMENTARY DNA; PRESENILIN 1; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; APOLIPOPROTEIN E4; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; GENE MUTATION; HUMAN; MISSENSE MUTATION; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; SENILE PLAQUE; ADULT; AGE; AGED; BLOOD; CELL LINE; CHEMISTRY; CULTURE MEDIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC TRANSFECTION; GENETICS; HETEROZYGOTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; SECRETION; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CELL LINE; CULTURE MEDIA, CONDITIONED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HETEROZYGOTE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PEPTIDE FRAGMENTS; PRESENILIN-1; PROGNOSIS; SEX FACTORS; TRANSFECTION;

EID: 0032587237     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.1999.0247     Document Type: Article

References (39)

1. Nat. Genet. 11:1995;219-222.
2. (1-42) in Alzheimer's disease: Differences between early- and late-onset AD and stability during the course of disease. Arch. Neurol. 56:1999;673-680.
3. Borchelt D. R., Thinakaran G., Eckman C. B., Lee M. K., Davenport F., Ratovitsky T., Prada C. M., Kim G., Seekins S., Yager D., Slunt H. H., Wang R., Seeger M., Levey A. I., Gandy S. E., Copeland N. G., Jenkins N. A., Price D. L., Younkin S. G., Sisodia S. S. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 17:1996;1005-1013.
4. Citron M., Eckman C. B., Diehl T. S., Corcoran C., Ostaszewski B. L., Xia W., Levesque G., Hyslop P., Younkin S. G., Selkoe D. J. Additive effects of PS1 and APP mutations on secretion of the 42-residue amyloid beta-protein. Neurobiol. Dis. 5:1998;107-116.
5. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson W. K., Lee M., Seubert P., Davis A., Kholodenko D., Motter R., Sherrington R., Perry B., Yao H., Strome R., Lieberburg I., Rommens J., Kim S., Schenk D., Fraser P., St-George H. P., Selkoe D. J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 3:1997;67-72.
6. Cruts M., Backhovens H., Wang S. Y., Van Gassen G., Theuns J., De Jonghe C., Wehnert A., De Voecht J., De Winter G., Cras P. Molecular genetic analysis of familial early-onset Alzheimer's disease linked to chromosome 14q24.3. Hum. Mol. Genet. 4:1995;2363-2371.
7. Cruts M., Van Broeckhoven C. Presenilin mutations in Alzheimer's disease. Hum. Mut. 11:1998a;183-190.
8. Cruts M., van Duijn C. M., Backhovens H., van-den Broeck M., Wehnert A., Serneels S., Sherrington R., Hutton M., Hardy J., St-George Hyslop P. H., Hofman A., Van Broeckhoven C. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum. Mol. Genet. 7:1998b;43-51.
9. De Jonghe C., Vanderhoeven I., Mercken M., Thinakaran G., Sisodia S. S., Martin J. J., Van Broeckhoven C., Hendriks L. In vitro and in vivo analysis of presenilin 1 processing. Arch. Physiol. Biochem. 104:1997;B30-B30.
10. De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K., Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 391:1998;387-390.
11. Duff K., Eckman C., Zehr C., Yu X., Prada C. M., Perez T. J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M. N., Holcomb L., Refolo L., Zenk B., Hardy J., Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 383:1996;710-713.
12. Gomez-Isla T., Wasco W., Pettingell W. P., Gurubhagavatula S., Schmidt S. D., Jondro P. D., McNamara M., Rodes L. A., DiBlasi T., Growdon W. B., Seubert P., Schenk D., Growdon J. H., Hyman B. T., Tanzi R. E. A novel presenilin-1 mutation: Increased beta-amyloid and neurofibrillary changes. Ann. Neurol. 41:1997;809-813.
13. Gravina S. A., Ho L., Eckman C. B., Long K. E., Otvos L., Younkin L. H., Suzuki N., Younkin S. G. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J. Biol. Chem. 270:1995;7013-7016.
14. Hendriks L., De Jonghe C., Lubke U., Woodrow S., Vanderhoeven I., Boons J., Cras P., Martin J. J., Van Broeckhoven C. Immunoreactivity of presenilin-1 and tau in Alzheimer's disease brain. Exp. Neurol. 149:1998;341-348.
15. Hendriks L., Thinakaran G., Harris C. L., De Jonghe C., Martin J. J., Sisodia S. S., Van Broeckhoven C. Processing of presenilin 1 in brains of patients with Alzheimer's disease and controls. Neuroreport. 8:1997;1717-1721.
16. Ishii K., Ii K., Hasegawa T., Shoji S., Doi A., Mori H. Increased A beta 42(43)-plaque deposition in early-onset familial Alzheimer's disease brains with the deletion of exon 9 and the missense point mutation (H163R) in the PS-1 gene. Neurosci. Lett. 228:1997;17-20.
17. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43). Neuron. 13:1994;45-53.
18. Jarrett J. T., Lansbury P. T. J. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie. Cell. 73:1993;1055-1058.
19. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D., Lieberburg I., Schenk D., Seubert P., McConlogue L. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 94:1997;1550-1555.
20. Kovacs D. M., Fausett H. J., Page K. J., Kim T. W., Moir R. D., Merriam D. E., Hollister R. D., Hallmark O. G., Mancini R., Felsenstein K. M., Hyman B. T., Tanzi R. E., Wasco W. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat. Med. 2:1996;224-229.
21. Lemere C. A., Lopera F., Kosik K. S., Lendon C. L., Ossa J., Saido T. C., Yamaguchi H., Ruiz A., Martinez A., Madrigal L., Hincapie L., Arango J. C., Anthony D. C., Koo E. H., Goate A. M., Selkoe D. J. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat. Med. 2:1996;1146-1150.
22. Li X., Greenwald I. Additional evidence for an eight-transmembrane-domain topology for Caenorhabditis elegans and human presenilins. Proc. Natl. Acad. Sci. USA. 95:1998;7109-7114.
23. Mann D. M., Iwatsubo T. Diffuse plaques in the cerebellum and corpus striatum in Down's syndrome contain amyloid beta protein (A beta) only in the form of A beta 42(43). Neurodegeneration. 5:1996a;115-120.
24. Mann D. M., Iwatsubo T., Cairns N. J., Lantos P. L., Nochlin D., Sumi S. M., Bird T. D., Poorkaj P., Hardy J., Hutton M., Prihar G., Crook R., Rossor M. N., Haltia M. Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: Predominance of Abeta42(43). Ann. Neurol. 40:1996b;149-156.
25. Mann D. M., Iwatsubo T., Nochlin D., Sumi S. M., Levy L. E., Bird T. D. Amyloid (Abeta) deposition in chromosome 1-linked Alzheimer's disease: The Volga German families. Ann. Neurol. 41:1997;52-57.
26. Martin J. J., Gheuens J., Bruyland M., Cras P., Vandeberghe A., Masters C. L., Beyreuther K., Dom R., Ceuterick C., Lübke U. Early-onset Alzheimer's disease in 2 large Belgian families. Neurology. 41:1991;62-68.
27. Martins R. N., Turner B. A., Carroll R. T., Sweeney D., Kim K. S., Wisniewski H. M., Blass J. P., Gibson G. E., Gandy S. High levels of amyloid-beta protein from S182 (Glu246) familial Alzheimer's cells. Neuroreport. 7:1995;217-220.
28. Mehta N. D., Refolo L. M., Eckman C., Sanders S., Yager D., Perez T. J., Younkin S., Duff K., Hardy J., Hutton M. Increased Abeta42(43) from cell lines expressing presenilin 1 mutations. Ann. Neurol. 43:1998;256-258.
29. Oyama F., Sawamura N., Kobayashi K., Morishima-Kawashima M., Kuramochi T., Ito M., Tomita T., Maruyama K., Saido T. C., Iwatsubo T., Capell A., Walter J., Grunberg J., Ueyama Y., Haass C., Ihara Y. Mutant presenilin 2 transgenic mouse: Effect on an age-dependent increase of amyloid beta-protein 42 in the brain. J. Neurochem. 71:1998;313-322.
30. Perez-Tur J., Froelich S., Prihar G., Crook R., Baker M., Duff K., Wragg M., Busfield F., Lendon C., Clark R. F. A mutation in Alzheimer's disease destroying a splice acceptor site in the presenilin-1 gene. Neuroreport. 7:1995;297-301.
31. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T. D., Hardy J., Hutton M., Kukull W., Larson E., Levy L. E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2:1996;864-870.
32. Selkoe D. Alzheimer's disease: A central role for amyloid. Neuropath. Exp. Neurol. 53:1994;438-447.
33. Strittmatter W. J., Saunders A. M., Schmechel D., Pericak V. M., Enghild J., Salvesen G. S., Roses A. D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90:1993;1977-1981.
34. Thinakaran G., Borchelt D. R., Lee M. K., Slunt H. H., Spitzer L., Kim G., Ratovitsky T., Davenport F., Nordstedt C., Seeger M., Hardy J., Levey A. I., Gandy S. E., Jenkins N. A., Copeland N. G., Price D. L., Sisodia S. S. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron. 17:1996;181-190.
35. Tysoe C., Whittaker J., Xuereb J., Cairns N., Cruts M., Van Broeckhoven C., Wilcock G., Rubinsztein D. C. A presenilin-1 truncating mutation is present in two cases with autopsy-confirmed early-onset Alzheimer's disease. Am. J. Hum. Genet. 62:1998;70-76.
36. Van Broeckhoven C., Backhovens H., Cruts M., Martin J. J., Crook R., Houlden H., Hardy J. APOE genotype does not modulate age of onset in families with chromosome 14 encoded Alzheimer's disease. Neurosci. Lett. 169:1994;179-180.
37. van Duijn C., de K. P., Cruts M., Wehnert A., Havekes L. M., Hofman A., Van B. C. Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nat. Genet. 7:1994;74-78.
38. Wenham P. R., Price W. H., Blandell G. Apolipoprotein E genotyping by one-stage PCR [letter]. Lancet. 337:1991;1158-1159.
39. Xia W., Zhang J., Kholodenko D., Citron M., Podlisny M. B., Teplow D. B., Haass C., Seubert P., Koo E. H., Selkoe D. J. Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J. Biol. Chem. 272:1997;7977-7982.